NeurologyLive® Friday 5 — March 20, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more buttons for more details and information about each highlight.

1: Navigating Insurance Barriers for Emerging Neuromuscular Therapies: Omer A. Abdul Hamid, MD

In an interview at the 2026 MDA Conference, Omer A. Abdul Hamid, MD, a neurologist at Nemours Children's Hospital, discussed practical strategies for navigating insurance to ensure patients can access newly available neuromuscular therapies. [WATCH TIME: 3 minutes]

2: At the Intersection of Oncology and Neurology: Increasing Recognition of Paraneoplastic Neurologic Syndromes

In this new exclusive NeurologyLive feature, neuro-oncologists Ditte Primdahl, MD, and Shailee Samir Shah, MD, both of Northwestern Medicine, discussed diagnostic challenges, treatment strategies, and the need for clinical vigilance regarding paraneoplastic neurologic syndromes, as they remain underrecognized in oncology.

3: Exploring Long-Term Safety and Real-World Use of Givinostat in Duchenne Muscular Dystrophy: John F. Brandsema, MD

In an interview at the 2026 MDA Conference, John F. Brandsema, MD, child neurologist at Children’s Hospital of Philadelphia, discussed the real-world safety data of givinostat use in patients with Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

4: NeuroVoices: Tanuja Chitnis, MD, on EBNA-1 Antibodies to Distinguish MS, MOGAD, and NMOSD

In our latest NeuroVoices Q&A, Tanuja Chitnis, MD, division chief of neuroimmunology at Brigham and Women’s Hospital, discusses longitudinal EBNA-1 antibody data and its potential role as a complementary biomarker to distinguish MS from related neuroinflammatory diseases.

5: Bridging Imaging Biomarkers and Clinical Outcomes in Multiple Sclerosis Research: Daniel Ontaneda, MD, PhD

In an interview at the 2026 ACTRIMS Forum, Daniel Ontaneda, MD, PhD, staff neurologist at Cleveland Clinic’s Mellen Center for MS, provided thoughts on how radiologic biomarkers may help shape the next generation of multiple sclerosis clinical trials. [WATCH TIME: 3 minutes]

Click here to view our latest video interview shorts with neurology experts.